Dariohealth reports second quarter 2023 financial and operating results

- generated sequential b2b recurring revenue growth for the tenth consecutive quarter - revenues of $6.15 million (pre-announced), compared to $6.18 million in the second quarter of 2022, a 0.5% decrease resulting from a delay with one of our strategic partners - improved gross profit margin to 33.7% of revenues for the second quarter of 2023, up from 18.4% for the second quarter of 2022 - improved proforma gross profit margin to 51.5% of revenues for the second quarter of 2023, up from 36.1% for the second quarter of 2022·  - reduced operating expenses by 13% in the second quarter of 2023, as compared to the second quarter of 2022 - launched hypertension solution with a large regional health plan through partnership with solera and signed an expansion to that contract to include diabetes - announced contract with pharmacy benefit manager, medone, through dario's partnership with sanofi - cash and cash equivalents balance as of the end of the second quarter of 2023 of $52.6 million, which provides estimated runway through 2025 - company to host investor conference call and webcast at 8:30 a.m. et today new york , aug. 10, 2023 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, today reported financial results for the second quarter 2023 and provided a corporate and commercial update.
DRIO Ratings Summary
DRIO Quant Ranking